Sector News

Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion

February 14, 2017
Life sciences

Botox maker Allergan Plc agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc (ZLTQ.O), adding a system that it says helps people slim down by freezing fat away to the company’s line-up of aesthetic products.

Allergan said it would benefit from the cross-selling opportunities for consumers of Zeltiq’s CoolSculpting System, which uses cooling to kill fat cells, as well as customers of its own facial injectible products.

“Demand for both procedures is high and this is similar to pouring more gas on the fire,” Allergan Chief Commercial Officer Bill Meury said on a call with investors.

The Botox maker agreed to pay $56.50 per Zeltiq share, or a premium of 14.4 percent to the company’s Friday close. Zeltiq’s shares rose 12.8 percent to $55.72 in midday trading on Monday.

Zeltiq’s process was created after two scientists at Harvard University noticed that some children who ate popsicles got dimples in their cheeks, according to Zeltiq’s website. They discovered that the popsicles were eliminating small pockets of fat cells.

Insurers do not cover Zeltiq’s CoolSculpting System, meaning the bulk of the company’s more than $350 million in 2016 sales was paid directly by consumers. Allergan said it has been targeting so-called “cash-pay” businesses, which is a model it uses for some of its Botox sales and other aesthetic offerings.

CoolSculpting is approved by the U.S. Food and Drug Administration.

Dublin-based Allergan, led by its Chief Executive Brent Saunders, has struck a number of deals since its $160 billion merger with Pfizer Inc collapsed in April. Those have included its $2.9 billion purchase of regenerative medicine business LifeCell Corp and the $1.5 billion acquisition of biotech company Vitae Pharmaceuticals.

Earlier this month, Saunders set lofty expectations for its injection Kybella – used to diminish fat under the chin, leaving surrounding tissue largely unaffected – for 2017, and expressed an interest in continued deal making.

In the three months ended Dec. 31, total medical aesthetic product sales accounted for 28 percent of Allergan’s net revenue.

Allergan, which estimates that body contouring is a $4 billion market, said the transaction is expected to close in the second half of 2017.

Shares of Allergan rose $1.27, or 0.5 percent, to $247.63 in midday trading on the New York Stock Exchange.

Moelis & Co is Allergan’s financial adviser, while Debevoise & Plimpton LLP serve as legal counsel. Guggenheim Securities is Zeltiq’s financial adviser, while Cooley LLP will provide legal advice.

By Michael Erman and Natalie Grover

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.